alvimopan (Entereg, ADL-8-2698)
Jump to navigation
Jump to search
Indications
- prevention of post-operative ileus
- decreases postoperative ileus after abdominal surgery in patients with inflammatory bowel disease[3]
- reduces post-operative nausea & vomiting without increased need for post-operative analgesia
Precautions:
- hospitals must be specially certified before using the drug
Dosage
- 6 mg just before surgery, then 6 mg BID
- limited to 15 doses
Pharmacokinetics
- poorly absorbed from GI tract
- does not readily cross blood brain barrier
Adverse effects
- hypocalcemia
- anemia
- constipation, dyspepsia, flatulence
- increased risk of myocardial infarction?[2]
Mechanism of action
- investigational opioid receptor antagonist (10/01)
- reduces post-operative nausea & vomiting
More general terms
References
- ↑ Taguchi A, Sharma N, Saleem RM, Sessler DI, Carpenter RL, Seyedsadr M, Kurz A. Selective postoperative inhibition of gastrointestinal opioid receptors. N Engl J Med. 2001 Sep 27;345(13):935-40. PMID: https://www.ncbi.nlm.nih.gov/pubmed/11575284 Free Article
- ↑ 2.0 2.1 FDA press release http://www.fda.gov/bbs/topics/NEWS/2008/NEW01838.html
- ↑ 3.0 3.1 Bachert A. Alvimopan Speeds GI Recovery in IBD Patients - Significantly decreased length of stay, researchers reported at AIBD. MedPage Today, Nov 10, 2017
Jang J, et al The use of alvimopan as prophylaxis against post-operative ileus after bowel resection in patients with inflammatory bowel disease. Advances in Inflammatory Bowel Diseases (AIBD) 2017 Poster 004.